AbbVie Inc. (ABBV) Company Profile
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
News about ABBV
Centre Asset Management LLC Has $5.15 Million Holdings in AbbVie Inc (ABBV)
Centre Asset Management LLC trimmed its holdings in shares of AbbVie Inc (NYSE:ABBV) by 6.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 55,600 shares of the company’s stock after selling 3,590 shares dur...Read More>>>
Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential
Needless to say, the biotech world has had a volatile 18 months. Some of the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, are still looking like top plays for investors. However, you can bet that the ...Read More>>>
How Do Drugs Compete Against Each Other?
It's easy to pick a winner when a medication is the only treatment for its indication. But when there's more than one drug on the market, how can investors tell which one will ultimately win more patient share? In this prerecorded episode of Indust...Read More>>>
Should AbbVie Be More Concerned About Its California Case for Humira?
AbbVie Inc. (NYSE: ABBV) shares took a dip on Wednesday after it was announced that the pharmaceutical giant would be facing a lawsuit from the California Department of Insurance in regards to alleged kickbacks given to health care providers for pres...Read More>>>
3 Top Healthcare Stocks to Buy Right Now
Healthcare stocks are handily outpacing the S&P 500 index so far in 2018. With the aging demographics in the U.S. and other major countries serving as a significant tailwind, it's possible that healthcare will remain a hot area for investors for ...Read More>>>